Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01450644
Other study ID # CCR3669
Secondary ID
Status Recruiting
Phase Phase 2
First received October 7, 2011
Last updated December 7, 2011
Start date October 2011
Est. completion date January 2013

Study information

Verified date December 2011
Source Royal Marsden NHS Foundation Trust
Contact Dr Sabrina Bajwah
Phone 02078082761
Email sabrina.bajwah@kcl.ac.uk
Is FDA regulated No
Health authority United Kingdom: National Health ServiceUnited Kingdom: National Institute for Health ResearchUnited Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

The investigators hypothesise that H2H will result in improved symptom control and quality of life and may be more cost-effective than standard best practice.

Interstitial Lung Disease (ILD) is a lung condition characterised by progressive scarring - known as fibrosis. This is especially seen in patients with idiopathic pulmonary fibrosis (IPF). There around 2,000 new patients diagnosed in the UK every year with a similar number of deaths.

Fibrotic-ILD causes breathing to slowly deteriorate and as there is no cure, an estimated two-thirds of patients die within five years of diagnosis. Patients suffer from many symptoms including shortness of breath, cough, low mood and fatigue which are currently being poorly managed. In addition, these patients suffer a poor health related quality of life whilst dying from their disease.

In the later stages of their disease, these patients often end up in hospital (see appendix 1a) when there is no proven or effective treatment. Many die there despite wishing to be looked after and die at home. These patients rarely receive palliative care which may help to improve their symptoms, quality of life, address end of life planning needs and prevent hospital admission. The Hospital2Home case conference conducted in the patient's home (or place of their choice) aims to address this. At the case conference involving the patient, their carers, a specialist nurse, and all the community health professionals, a care plan specific to the patient will be developed. Each health professional will be aware of their responsibility and duties. The investigators will look at whether this results in better symptom control and better quality of life for the patient and their carer. The investigators will also examine whether this prevents emergency hospital admission and allows patients to die in their preferred place. The investigators will compare patients who receive the service immediately with those who receive it after a delay.


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date January 2013
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

Patients i)Clinical diagnosis of PIF-ILD and a 30% survival at 1 year according to the validated prognostic tool developed by Professor Wells.(Appendix 5)

ii) Aged 18 years or over

iii) Any patient who does not meet any of the exclusion criteria

Carers i) The informal caregivers of patients specified above, who can be significant others, relatives, friends or neighbours

ii) Aged 18 years or over

iii) Any carer who does not meet the exclusion criteria

Health professional Primary health professional in contact with patient able to give consent

Exclusion Criteria:

Patients/informal caregiver i) Any patient/ informal caregiver unable to give informed consent

ii) Any patient/informal caregiver less than 18 years of age

iii) Participants who are unable to understand/speak English

iv) Participants who are remaining as an inpatient in the hospital or being transferred to another inpatient facility (eg hospice unit, for terminal care)

v) Participants whose prognosis is less than 1 week or judged too unwell by the research team to take part in serial interviews

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Other:
The Hospital2Home Service
This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.

Locations

Country Name City State
United Kingdom The Royal Brompton NHS Foundation Trust London
United Kingdom The Royal Marsden NHS Foundation Trust London

Sponsors (1)

Lead Sponsor Collaborator
Royal Marsden NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in POS scores from week 4 to baseline for each group POS scores evaluate symptoms and palliative concerns using the Palliative Care Outcome Scale (POS). This comprises eight questions on anxiety, patient and informal caregiver concerns, and practical needs, each rated 0-4. This scoring system will ensure that there is some ongoing data available if the patient becomes unwell and is no longer able to complete the study. 15 months No
Secondary comparison of the patient and informal caregiver POS in this study to see how inter-changeable/reliable the 2 assessments are At each interview, service use questions will be asked which will record the frequency and types of health/social services received in order that an accurate evaluation of cost of care per patient can be made. In addition semi-structured qualitative interviews will be conducted with patients, informal caregivers and health professionals. Prompts will include views of the case conference, the guidelines and what level of input was needed after the case conference. A record will be made of when and where the patient dies. 15 months No
See also
  Status Clinical Trial Phase
Completed NCT02217423 - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy N/A
Withdrawn NCT02253667 - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients N/A
Completed NCT01679301 - Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator N/A
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Terminated NCT00966823 - Fetal Tracheal Balloon Study in Diaphragmatic Hernia Phase 2
Completed NCT00139152 - Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair Phase 4
Completed NCT00052052 - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Completed NCT00013949 - Cardiovascular Vulnerability to Particulate Exposure N/A
Recruiting NCT02963467 - Effect of Smoking on Ventilation-Perfusion Ratio N/A
Recruiting NCT02965300 - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis N/A
Enrolling by invitation NCT02946658 - Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders Phase 1/Phase 2
Recruiting NCT02913365 - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis N/A
Completed NCT01735526 - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation N/A
Completed NCT01952002 - Clinical Safety for the Inspiratory Muscle Training N/A
Completed NCT01215279 - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) Phase 2
Completed NCT01153321 - Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Completed NCT00837681 - Pulmonary Complications of Hematopoietic Stem Cell Transplantation N/A
Completed NCT02055222 - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Completed NCT01222442 - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart Phase 1
Recruiting NCT02723474 - A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease N/A